SG10201903381TA - Artificial nucleic acid molecules - Google Patents

Artificial nucleic acid molecules

Info

Publication number
SG10201903381TA
SG10201903381TA SG10201903381TA SG10201903381TA SG10201903381TA SG 10201903381T A SG10201903381T A SG 10201903381TA SG 10201903381T A SG10201903381T A SG 10201903381TA SG 10201903381T A SG10201903381T A SG 10201903381TA SG 10201903381T A SG10201903381T A SG 10201903381TA
Authority
SG
Singapore
Prior art keywords
nucleic acid
utr
artificial nucleic
acid molecules
acid sequence
Prior art date
Application number
SG10201903381TA
Inventor
Andreas Thess
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG10201903381TA publication Critical patent/SG10201903381TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Artificial nucleic acid molecules The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3’-untranslated region element (3’-UTR) element 5 comprising a nucleic acid sequence which is derived from the 3’-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3’-UTR element comprising a nucleic acid sequence which is derived from the 3’-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging 10 protein expression from a nucleic acid sequence comprising such 3’-UTR element. (No Suitable figure) 163
SG10201903381TA 2013-12-30 2014-12-30 Artificial nucleic acid molecules SG10201903381TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2013003946 2013-12-30

Publications (1)

Publication Number Publication Date
SG10201903381TA true SG10201903381TA (en) 2019-05-30

Family

ID=49920310

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201903381TA SG10201903381TA (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules
SG11201603144QA SG11201603144QA (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201603144QA SG11201603144QA (en) 2013-12-30 2014-12-30 Artificial nucleic acid molecules

Country Status (13)

Country Link
US (2) US10047375B2 (en)
JP (2) JP6704850B2 (en)
KR (1) KR102399799B1 (en)
CN (2) CN111304231A (en)
AU (1) AU2014375402B2 (en)
BR (1) BR112016014462A2 (en)
CA (1) CA2927862C (en)
DK (1) DK3090053T3 (en)
ES (1) ES2712092T3 (en)
MX (2) MX2016008551A (en)
RU (1) RU2717986C2 (en)
SG (2) SG10201903381TA (en)
WO (1) WO2015101414A2 (en)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
EP2717893B1 (en) 2011-06-08 2019-05-08 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
CN104321432B (en) * 2012-03-27 2018-08-10 库瑞瓦格股份公司 Include the artificial nucleic acid molecule of 5 ' TOP UTR
RU2750261C2 (en) * 2012-03-27 2021-06-25 Кьюрвак Аг Artificial molecules of nucleic acids for improved expression of proteins and peptides
CN104519915A (en) 2012-06-08 2015-04-15 夏尔人类遗传性治疗公司 Pulmonary delivery of mRNA to non-lung target cells
CN105073135A (en) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 Combination of vaccination and inhibition of the PD-1 pathway
EP3446712A1 (en) 2013-03-14 2019-02-27 Translate Bio Ma, Inc. Cftr mrna compositions and related methods and uses
SI2970456T1 (en) 2013-03-14 2022-01-31 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
JP7019233B2 (en) 2013-07-11 2022-02-15 モデルナティエックス インコーポレイテッド Compositions and Methods of Use Containing Synthetic polynucleotides and Synthetic sgRNAs Encoding CRISPR-Related Proteins
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
CN105473158B (en) 2013-08-21 2021-04-13 库瑞瓦格股份公司 Respiratory Syncytial Virus (RSV) vaccine
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
JP6704850B2 (en) 2013-12-30 2020-06-03 キュアバック アーゲー Artificial nucleic acid molecule
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
SG11201608605QA (en) 2014-06-10 2016-12-29 Curevac Ag Methods and means for enhancing rna production
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
PL4023755T3 (en) 2014-12-12 2023-12-27 CureVac SE Artificial nucleic acid molecules for improved protein expression
CA2966092A1 (en) * 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
EP4026568A1 (en) 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
CN108064176A (en) 2015-04-22 2018-05-22 库瑞瓦格股份公司 For treating the composition containing RNA of tumor disease
CN107889503A (en) 2015-04-30 2018-04-06 库瑞瓦格股份公司 Poly- (N) polymerase of immobilization
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
RU2742993C2 (en) 2015-05-15 2021-02-12 Куревак Аг Prime-boost modes involving introduction of at least one mrna structure
CN107530448A (en) 2015-05-20 2018-01-02 库瑞瓦格股份公司 Include long-chain RNA dry powder composite
EP3298142B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
US11608513B2 (en) 2015-05-29 2023-03-21 CureVac SE Method for adding cap structures to RNA using immobilized enzymes
PT4108769T (en) 2015-05-29 2023-10-10 Curevac Mfg Gmbh A method for producing and purifying rna, comprising at least one step of tangential flow filtration
HUE067372T2 (en) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
AU2016316439B2 (en) 2015-08-28 2022-02-24 CureVac SE Artificial nucleic acid molecules
US12109274B2 (en) * 2015-09-17 2024-10-08 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP4086269A1 (en) 2015-10-16 2022-11-09 ModernaTX, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066793A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
EP3364983A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Respiratory virus vaccines
EP4212510A1 (en) 2015-10-28 2023-07-19 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
CA3009551C (en) 2015-12-22 2022-12-13 Curevac Ag Method for producing rna molecule compositions
RS63051B1 (en) 2015-12-22 2022-04-29 Modernatx Inc Compounds and compositions for intracellular delivery of agents
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
LT3458083T (en) 2016-05-18 2023-02-10 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
KR20190029576A (en) 2016-06-09 2019-03-20 큐어백 아게 Nucleic acid carboxy hybrid carrier
WO2017218524A1 (en) 2016-06-13 2017-12-21 Rana Therapeutics, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3030701A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
CN110582304A (en) 2016-12-08 2019-12-17 库尔维科公司 RNA for treating or preventing liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
MA47603A (en) 2017-02-27 2020-01-01 Translate Bio Inc NEW ARNM CFTR WITH OPTIMIZED CODONS
EP4186888A1 (en) 2017-03-15 2023-05-31 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
EP3595727A1 (en) 2017-03-15 2020-01-22 ModernaTX, Inc. Lipid nanoparticle formulation
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
BR112019015244A2 (en) 2017-03-24 2020-04-14 Curevac Ag nucleic acids encoding proteins associated with crispr and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200975A1 (en) 2017-04-27 2018-11-01 Vanderbilt University Hepatitis c virus gene sequences and methods of use therefor
JP7297676B2 (en) 2017-04-28 2023-06-26 アクイタス セラピューティクス インコーポレイテッド Novel carbonyl lipids and lipid nanoparticle formulations for nucleic acid delivery
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
JP7355731B2 (en) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods of preparing modified rna
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
MX2020003995A (en) * 2017-10-19 2020-07-22 Curevac Ag Novel artificial nucleic acid molecules.
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
EP3727428A1 (en) 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CA3095125A1 (en) * 2018-03-27 2019-10-03 Factor Bioscience Inc. Nucleic acid-based therapeutics
EP3781591A1 (en) 2018-04-17 2021-02-24 CureVac AG Novel rsv rna molecules and compositions for vaccination
JP7410135B2 (en) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
BR112021014845A2 (en) 2019-01-31 2021-11-03 Modernatx Inc Lipid Nanoparticle Preparation Methods
CA3128488A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Vortex mixers and associated methods, systems, and apparatuses thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CA3134944A1 (en) 2019-03-25 2020-10-01 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
CN112190591B (en) * 2019-07-08 2021-12-17 中国农业科学院兰州兽医研究所 Use of ribosomal protein RPL13 inhibitor for the preparation of a medicament for inhibiting IRES-dependent translation of viral replication
CA3168902A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
CA3170150A1 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021204175A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
CN111621588A (en) * 2020-06-08 2020-09-04 华中农业大学 Molecular marker for breeding bright peel tomato variety and application thereof
US20220331414A1 (en) 2020-06-30 2022-10-20 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116096702A (en) 2020-07-16 2023-05-09 爱康泰生治疗公司 Cationic lipids for lipid nanoparticles
AU2021328980A1 (en) 2020-08-20 2023-03-09 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN114717230B (en) * 2021-01-05 2024-09-03 麦塞拿治疗(香港)有限公司 Cell-free and carrier-free in vitro RNA transcription method of fibroblast growth factor mRNA and nucleic acid molecule
CN114717238A (en) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA transcription of epidermal growth factor mRNA
US20230000970A1 (en) 2021-01-11 2023-01-05 Modernatx, Inc. Seasonal rna influenza virus vaccines
CN116615472A (en) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
JP2024503698A (en) 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド Mutant strain-based coronavirus vaccine
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
JP2024511346A (en) 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Therapeutic use of SARS-COV-2 mRNA domain vaccines
JP2024514182A (en) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド Respiratory virus combination vaccine
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
CN116472275A (en) 2021-05-24 2023-07-21 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
JP2024528418A (en) 2021-06-18 2024-07-30 サノフイ Multivalent influenza vaccine
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
TW202325263A (en) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 Acyclic lipids and methods of use thereof
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
KR20240090186A (en) 2021-10-08 2024-06-21 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 Lipid Compounds and Lipid Nanoparticle Compositions
KR20240090727A (en) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. mRNA vaccine composition
EP4426343A1 (en) 2021-11-05 2024-09-11 Sanofi Respiratory syncytial virus rna vaccine
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
AU2022398450A1 (en) 2021-11-23 2024-06-06 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
WO2023102373A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
CN118647600A (en) 2021-12-16 2024-09-13 爱康泰生治疗公司 Lipids for lipid nanoparticle formulations
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
AU2022422983A1 (en) 2021-12-23 2024-05-16 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
EP4452928A1 (en) 2021-12-23 2024-10-30 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
AU2023265481A1 (en) 2022-05-06 2024-12-19 Sanofi Signal sequences for nucleic acid vaccines
TW202400784A (en) * 2022-05-13 2024-01-01 大陸商上海瑞宏迪醫藥有限公司 Nucleic acid constructs comprising utrs and applications thereof
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024094876A1 (en) 2022-11-04 2024-05-10 Sanofi Methods for messenger rna tailing
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024126809A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna encoding influenza virus-like particle
WO2024126847A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna recombinant capping enzymes
WO2024133884A2 (en) 2022-12-23 2024-06-27 Sanofi Optimized tailing of messenger rna
CN118574931A (en) * 2022-12-29 2024-08-30 传信生物医药(苏州)有限公司 Novel 5' -untranslated region element and application thereof
CN116159127B (en) * 2023-01-17 2024-04-02 西安交通大学医学院第一附属医院 Use of acidic ribosomal protein P2 in the treatment of anxiety disorders
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
CN116004696B (en) * 2023-02-01 2024-03-29 郑州贝贝生物科技有限公司 3' -UTR (UTR) stem-loop added structure gene capable of being combined with IRES (IRES), application thereof and mRNA (messenger ribonucleic acid) expression system
US20240299524A1 (en) 2023-03-02 2024-09-12 Sanofi Compositions for use in treatment of chlamydia
WO2024184489A1 (en) 2023-03-07 2024-09-12 Sanofi Manufacture of messenger rna with kp34 polymerase
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
JP2001518804A (en) 1997-03-21 2001-10-16 エンゾー セラピューティクス インコーポレイテッド Vectors and viral vectors and packaging cell lines for propagating them
WO2001007590A2 (en) * 1999-07-27 2001-02-01 Syngenta Participations Ag Chimeric genes for plastid expression
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
ATE464317T1 (en) 2001-06-05 2010-04-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT FOR GENE THERAPY
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
WO2003038049A2 (en) 2001-10-29 2003-05-08 Renovis, Inc. Method for isolating cell-type specific mrnas
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP2500437B1 (en) 2003-01-21 2016-11-30 PTC Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
EP1685251B1 (en) * 2003-10-10 2014-03-05 PowderJect Vaccines, Inc. Nucleic acid constructs
DE102004035227A1 (en) 2004-07-21 2006-02-16 Curevac Gmbh mRNA mixture for vaccination against tumor diseases
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
RS63964B1 (en) 2005-08-23 2023-03-31 Univ Pennsylvania Rna containing modified nucleosides and methods of use thereof
ATE497009T1 (en) * 2005-12-12 2011-02-15 King Faisal Specialist Hospital And Res Ct 3-NON-TRANSLATED HYBRID AREAS SUITABLE FOR EFFICIENT PROTEIN EXPRESSION IN MAMMAL CELLS
DE102006035618A1 (en) 2006-07-31 2008-02-07 Curevac Gmbh New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006061015A1 (en) 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2009155950A1 (en) * 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Centre Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2736430A1 (en) * 2008-09-30 2010-04-08 Abbott Laboratories Improved antibody libraries
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
KR102049161B1 (en) * 2010-03-23 2019-11-26 인트렉손 코포레이션 Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
CN107648604A (en) 2010-07-30 2018-02-02 库瑞瓦格股份公司 The purposes of polymer support load compound and polymer support
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
CN103180443B (en) * 2010-09-01 2016-01-13 萨拉基尼克有限公司 For the nucleic acid fragment from ribosomal protein promotor of reinforcing gene expression
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
RU2750261C2 (en) * 2012-03-27 2021-06-25 Кьюрвак Аг Artificial molecules of nucleic acids for improved expression of proteins and peptides
CN104321432B (en) 2012-03-27 2018-08-10 库瑞瓦格股份公司 Include the artificial nucleic acid molecule of 5 ' TOP UTR
SG11201405542UA (en) 2012-03-27 2014-10-30 Curevac Gmbh Artificial nucleic acid molecules
WO2013174409A1 (en) 2012-05-25 2013-11-28 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
CN105473158B (en) 2013-08-21 2021-04-13 库瑞瓦格股份公司 Respiratory Syncytial Virus (RSV) vaccine
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
JP6704850B2 (en) 2013-12-30 2020-06-03 キュアバック アーゲー Artificial nucleic acid molecule
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Also Published As

Publication number Publication date
CA2927862A1 (en) 2015-07-09
MX2016008551A (en) 2016-09-26
DK3090053T3 (en) 2019-02-25
KR102399799B1 (en) 2022-05-18
JP2020184995A (en) 2020-11-19
MX2020003245A (en) 2020-07-20
US20220136001A1 (en) 2022-05-05
CA2927862C (en) 2024-01-23
US20170029847A1 (en) 2017-02-02
US10047375B2 (en) 2018-08-14
SG11201603144QA (en) 2016-07-28
AU2014375402B2 (en) 2020-10-01
KR20160104062A (en) 2016-09-02
ES2712092T3 (en) 2019-05-09
JP6704850B2 (en) 2020-06-03
JP2017502670A (en) 2017-01-26
WO2015101414A3 (en) 2015-10-08
BR112016014462A2 (en) 2017-10-24
JP6997251B2 (en) 2022-01-17
RU2016131391A (en) 2018-02-02
RU2016131391A3 (en) 2018-08-23
CN105874072A (en) 2016-08-17
RU2717986C2 (en) 2020-03-27
CN111304231A (en) 2020-06-19
WO2015101414A2 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
SG10201903381TA (en) Artificial nucleic acid molecules
MX357803B (en) Artificial nucleic acid molecules.
MX2018001040A (en) Artificial nucleic acid molecules.
SG10201906673WA (en) Artificial nucleic acid molecules
MX358706B (en) Artificial nucleic acid molecules comprising a 5'top utr.
MX362981B (en) Artificial nucleic acid molecules for improved protein or peptide expression.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
SA518400424B1 (en) Antibody molecules for cancer treatment
EA201690529A1 (en) METHODS OF MODIFICATION OF CELL-HOST
MX2019006045A (en) Psma targeting trispecific proteins and methods of use.
MX2017004039A (en) Galnac phosphoramidites, nucleic acid conjugates thereof and their use.
PH12019500209A1 (en) Methods and compositions for gene expression in plants
WO2019135816A3 (en) Novel nucleic acid modifiers
MX2017014908A (en) Trispecific binding proteins and methods of use.
MX2016016713A (en) Processes and systems for nucleic acid sequence assembly.
MX2017008817A (en) Compositions and methods for protein glycosylation.
MX2017004285A (en) Biological indicator.
MX2021010668A (en) Cytokine fusion proteins.
MX2019006633A (en) Antibody formulations.
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
CR20150532A (en) PLANT REGULATING ELEMENTS AND ITS USES
MX2019004487A (en) Methods and compositions for the treatment of fabry disease.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
MX2013011996A (en) Methods for regulating sirtuin gene expression.